Evoke Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2011
Net Income	-7.79	-8.22	-8.54	-13.15	-7.13	-7.57	-12.23	-10.75	-12.12	-13.25	Upgrade
Depreciation & Amortization	0.13	0.04	0	0	0	0	0	0	0	0	Upgrade
Share-Based Compensation	1.13	1.46	1.88	1.63	1.37	1.54	1.82	1.71	1.5	1.1	Upgrade
Other Operating Activities	1.55	0.13	-5.69	4.9	-0.01	-0.95	1.69	0.33	0.12	0.64	Upgrade
Operating Cash Flow	-4.98	-6.6	-12.35	-6.63	-5.76	-6.98	-8.72	-8.71	-10.5	-11.5	Upgrade
Share Issuance / Repurchase	0	7.44	13.44	3.93	6.11	4.62	7.39	13.52	5.03	0.04	Upgrade
Debt Issued / Paid	0	0	0	5.1	0	0	0	-4.5	0	1.5	Upgrade
Other Financing Activities	-0.12	-0.15	-0.01	-	-	-	-	-	-	-0.08	Upgrade
Financing Cash Flow	-0.12	7.29	13.43	9.04	6.11	4.62	7.39	9.02	5.03	1.46	Upgrade
Net Cash Flow	-5.1	0.7	1.08	2.41	0.34	-2.36	-1.33	0.32	-5.46	-10.04	Upgrade
Free Cash Flow	-4.98	-6.6	-12.35	-6.63	-5.76	-6.98	-8.72	-8.71	-10.5	-11.5	Upgrade
Free Cash Flow Margin	-96.22%	-262.93%	-763.43%	-28801.07%	-	-	-	-	-	-	Upgrade
Free Cash Flow Per Share	-1.49	-2.10	-4.61	-3.12	-3.10	-5.04	-7.02	-11.19	-19.42	-22.88	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).